Long-acting beta2-agonists in asthma: safety concerns.
Wooltorton
Eric
E
D000318:Adrenergic beta-Agonists / Q000009:adverse effects* / Q000627:therapeutic use*; D000420:Albuterol / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D001249:Asthma / Q000188:drug therapy*; D004983:Ethanolamines / Q000009:adverse effects / Q000627:therapeutic use; D000068759:Formoterol Fumarate; D006801:Humans; D016032:Randomized Controlled Trials as Topic; D018343:Receptors, Adrenergic, beta-2; D012307:Risk Factors; D012449:Safety; D000068299:Salmeterol Xinafoate
D000318:Adrenergic beta-Agonists; D004983:Ethanolamines; D018343:Receptors, Adrenergic, beta-2; D000068299:Salmeterol Xinafoate; D000420:Albuterol; D000068759:Formoterol Fumarate